MED4

Across TCGA pan-cancer cohorts, MED4 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MED4 data layer compared with 20 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher MED4 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MED4 expression acts as an unfavorable survival marker.

LUSC and ACC are the cancer types where MED4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.209	0.760	<.001	12	view →
ACC	OS	Median	All	0.118	0.624	.038	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

MED4–LUSC (DFS)

Open the LUSC breakdown →